Stutter exacerbated by lithium in a pediatric patient with bipolar disorder

Annals of Pharmacotherapy

Volumn 45, Issue 10, 2011, Pages

  Gulack, Brian C ^a   Puri, Neil V ^b   Kim, Wun J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Drug induced stutter; Lithium

Indexed keywords

CLONIDINE; FAMOTIDINE; LITHIUM; MELATONIN; RISPERIDONE;

AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; BIPOLAR DISORDER; CASE REPORT; CHILD; CONDUCT DISORDER; DISEASE EXACERBATION; DISTRESS SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; MALE; MANIA; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; SCHOOL CHILD; STUTTERING; SUICIDAL IDEATION;

ANTIMANIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BIPOLAR DISORDER; CHILD; DRUG MONITORING; HUMANS; LITHIUM; MALE; SEVERITY OF ILLNESS INDEX; STUTTERING; TREATMENT OUTCOME;

EID: 80053982670     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q140     Document Type: Article

References (27)

1. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
2. Brady J. The pharmacology of stuttering: a critical review. Am J Psychiatry 1991;148:1309-16.
3. Brady J. Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol 1998;18:50-4. DOI 10.1097/00004714-199802000-00008
4. Catalano G, Robben D, Catalano M. Olanzapine for the treatment of acquired neurogenic stuttering. J Psychiatr Pract 2009;15:484-8. DOI 10.1097/01.pra.0000364292.93704.65
5. Van Wattum PJ. Stuttering improved with risperidone. J Am Acad Child Adolesc Psychiatry 2006;45:133. DOI 10.1097/01.chi.0000190465.55329.b0
6. Maguire G, Yu B, Franklin D, Riley G. Alleviating stuttering with pharmacological interventions. Expert Opin Pharmacother 2004;5:1565-71. DOI 10.1517/14656566.57.1565
7. Kumar A, Balan S. Fluoxetine for persistent developmental stuttering. Clin Neuropharmacol 2007;30:58-9. DOI 10.1097/01.wnf.0000240950.18821.19
8. Prasse J, Kikano G. Stuttering: an overview. Am Fam Physician 2008; 77:1271-6.
9. Ludlow C. Stuttering: dysfunction in a complex and dynamic system. Brain 2000;123:1983-4. DOI 10.1093/brain/123.10.1983
10. Netski AL, Piasecki M. Lithium-induced exacerbation of stutter. Ann Pharmacother 2001;35:961.
11. Aljacic-Gross V, Vetter S, Muller M, et al. Risk factors for stuttering: a secondary analysis of a large data base. Eur Arch Psychiatry Clin Neurosci 2010;260:279-86.
12. Bar K, Hager F, Sauer H. Olanzapine and clozapine-induced stuttering. Pharmacopsychiatry 2004;37: 131-4.
13. Wu J, Maguire G, Riley G, et al. Increased dopamine activity associated with stuttering. Neuroreport 1997;8:767-70. DOI 10.1097/00001756-199702100-00037
14. Maguire G, Riley G, Yu B. A neurological basis of stuttering? Lancet Neurol 2002;1:407. DOI 10.1016/S1474-4422(02)00217-X
15. Criswell SR, Perlmutter JS, Videen TO, et al. Reduced uptake of [18F]FDOPA PET in asymptomatic welders with occupational manganese exposure. Neurology 2011;76:1296-301.
16. Yee RE, Irwin I, Milonas C, et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 2001;16:838-48. DOI 10.1002/mds.1168
17. Adler L, Leong S, Delgado R. Drug-induced stuttering treated with propranolol. J Clin Psychopharmacol 1987;7:115-6.
18. Garvey M, Tollefson G. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987;44:269-72.
19. Aukst-Margetic B. Stuttering as a side-effect of divalproex sodium. Psychiatry Clin Neurosci 2008;62:748.
20. Product information. Lithobid (lithium carbonate). Marietta, GA: Solvay Pharmaceuticals, June 2011. http://www.lithobid.net/pdfs/LithobidPI.pdf
21. Ward M, Musa M, Bailey L. Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994;34:280-5.
22. Tavano A, Busan P, Borelli M, Pelamatti G. Risperidone reduces tic-like motor behaviors and linguistic dysfluencies in severe persistent developmental stuttering. J Clin Psychopharmacol 2011;31:131-4. DOI 10.1097/JCP.0b013e318205694f
23. Yadav D. Risperidone induced stuttering. Gen Hosp Psychiatry 2010;32:559. DOI 10.1016/j.genhosppsych.2010.01.004
24. Ranjan S, Sawhney V, Chandra P. Persistent developmental stuttering: treatment with risperidone. Aust N Z J Psychiatry 2006;40:193. DOI 10.1016/j.genhosppsych.2010.01.004
25. Maguire G, Riley G, Franklin D, Gottschalk L. Risperidone for the treatment of stuttering. J Clin Psychopharmacol 2000;20:479-82.
26. Lee H, Lee H, Kim L, Lee M, Suh K, Kwak D. A case of risperidone-induced stuttering. J Clin Psychopharmacol 2001;21:115-6. DOI 10.1097/00004714-200102000-00024
27. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.